EyRIS and Diabetes Singapore had a joint press conference to launch our partnership, on the 27th of January 2021. The A.I. technology uses a Deep Learning System (DLS), which thinks and makes decisions like human cognition, to differentiate those with or without the eye conditions. This technology provides automatically referable and non-referable recommendations to identify patients with signs indicating more than mild DR, suspicions of glaucoma and/or AMD. It reduces the time to detect and decide on referrals from 1 hour to just about 3 minutes.
At Diabetes Singapore, we currently use their A.I. technology for one of our services – eye screening (Diabetic Retinopathy Photography). This has brought huge satisfaction to our patients, our partners, and our staff. Our staff have been certified as competent to manage EyRIS SELENA+.